Physician profile
Mun K Hong
NPI 1124077870
$155,292.09
in general payments reported to CMS, 2019-2025
20 companies · $49K in 2025
The $49K reported for 2025 was more than what 97% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $2,586 · 2021: $8,750 · 2022: $14K · 2023: $25K · 2024: $34K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $106K · Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $106,440.00 |
| Food and Beverage | $1,039.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $135,215.39 | 2019-2025 | Vantageview, Navitor, Xience Skypoint |
| Chiesi USA, INC. | $10,372.32 | 2019-2025 | Kengreal |
| Edwards Lifesciences Corporation | $5,947.17 | 2024-2025 | Sapien 3 Ultra Resilia |
| W. L. Gore & Associates, INC. | $2,012.50 | 2023 | Product In Development |
| Astrazeneca Pharmaceuticals Lp | $283.25 | 2019-2025 | Farxiga |
| Endologix LLC | $150.00 | 2025 | Endocross Device, Torus Stent Graft System |
| Cvrx, INC. | $144.07 | 2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $141.20 | 2023-2024 | Camzyos, Eliquis |
| Amgen INC. | $141.07 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $140.50 | 2023-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2023 | Opsumit, Uptravi |
| Pfizer INC. | $125.00 | 2019 | |
| Cook Medical LLC | $106.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $100.00 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.14 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $76.17 | 2019-2025 | Glidesheath Slender, Angio-Seal, Tr Band |
| Cardinal Health 200 LLC | $75.41 | 2020 | |
| Boston Scientific Corporation | $26.82 | 2025 | Ingevity+ |
| Angiodynamics, INC. | $15.16 | 2023 | Smart Port Ct |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mun Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.